

Outpatient to Outdoorsy



Help your patients with osteoarthritis make the most of the outdoors with great savings on METACAM® (meloxicam) Oral Suspension or Solution for Injection!

Metacam®
(meloxicam)

Stock up November 1 - November 30, 2021

Buy 5 Bottles, Get 2 Free

KEEP ON SAVING!

Take advantage of this offer by claiming it multiple times, for a maximum of 10 free bottles of METACAM® (meloxicam) Oral Suspension or Solution for Injection.

THE DETAILS*

- Orders must be placed November 1 - November 30, 2021
- Orders cannot be cumulative and must be the same SKU
- Free product will be shipped with the order in the same SKU
- Can be combined with Preferred Portfolio Program Therapeutic discount
- Can be combined with BI-CONNECT™ 2% rebate offer †

Order Now!

Contact your Boehringer Ingelheim Sales Representative or order online at BI-CONNECT.com to receive an additional 2% rebate. †

IMPORTANT SAFETY INFORMATION: METACAM (meloxicam oral suspension) is for use in dogs only. METACAM (meloxicam) Solution for Injection is approved for use in dogs or cats (not indicated for osteoarthritis in cats). Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. As a class, cyclooxygenase inhibitory NSAIDs like METACAM may be associated with gastrointestinal, kidney, or liver side effects. Dogs should be evaluated for pre-existing conditions and currently prescribed medications prior to treatment with METACAM, then monitored regularly while on therapy. Concurrent use with another NSAID, corticosteroid, or nephrotoxic medication should be avoided or monitored closely. Please refer to the package insert or product website for complete product information.

* See full terms and conditions on the back

† See BI-CONNECT™ terms and conditions: https://docs.boehringer-ingelheim.com/2021_BIConnect_2%25_Terms_%26_Conditions.pdf

METACAM® (meloxicam) OFFER TERMS AND CONDITIONS

Only licensed veterinarians and/or veterinary clinics, who currently have an account in good standing with Boehringer Ingelheim Animal Health USA Inc. (“Company”), who are legal residents of any of the fifty (50) United States or the District of Columbia (“Eligible Customer”) are eligible to participate in this offer (the “Promotion”).

The Promotion runs and Orders must be placed between November 1, 2021 – November 30, 2021 (the “Promotion Period”).

Offer good only with a valid purchase of eligible METACAM® (meloxicam) SKUs:

- SKU 100944 METACAM SUSP 0.5MG 30ML
- SKU 136325 METACAM SUSP 1.5MG 10ML
- SKU136327 METACAM INJ 10ML
- SKU 138776 METACAM SUSP 0.5MG 15ML
- SKU 140335 METACAM SUSP 1.5MG 32ML
- SKU 140354 METACAM SUSP 1.5MG 100ML
- SKU 14064 METACAM SUSP 1.5MG 180ML.

Eligible Customers may purchase five (5) bottles of Qualifying Product and receive two (2) bottles of the same SKU. All Qualifying Product must be purchased on the same order. Each Eligible Customer may receive up to 10 free products during the Promotion Period.

Qualifying Orders purchased during the Promotion Period through BI-CONNECT.com qualify for an additional 2% rebate on the paid Qualifying Product. Paid Qualifying Product can be combined with the Preferred Portfolio Program Therapeutic discount. Good only in continental U.S. and Hawaii.

Company reserves the right to restrict any Eligible Customer’s participation in this Promotion, and to cancel or amend this Promotion, at any time for any reason, in Company’s sole discretion.

All sales are subject to the Boehringer-Ingelheim Animal Health Vet-Exclusive Products US Sales Policy available at bi-connect.com/salespolicy.

Qualifying Products purchased during the Promotion Period and returned may be credited at 85% of the original purchase price.

Offer valid while supplies last.

Void where prohibited or restricted by law. All federal, state and local laws and regulations apply.

Orders received after the Promotion Period will need an exception request.

All exceptions will need to be requested through the Brand Manager of METACAM for approval.

Brief Summary

Metacam® (meloxicam oral suspension)

1.5 mg/mL (equivalent to 0.05 mg per drop) / 0.5 mg/mL (equivalent to 0.02 mg per drop)
Non-steroidal anti-inflammatory drug for oral use in dogs only

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Warning: Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information.

Description: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each milliliter of METACAM Oral Suspension contains meloxicam equivalent to 0.5 or 1.5 milligrams and sodium benzoate (1.5 milligrams) as a preservative. The chemical name for Meloxicam is 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The formulation is a yellowish viscous suspension with the odor of honey.

Indications: METACAM Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Contraindications: Dogs with known hypersensitivity to meloxicam should not receive METACAM Oral Suspension. Do not use METACAM Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only.

As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about METACAM.

Precautions: The safe use of METACAM Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders.

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after administration of the total daily dose of METACAM Oral Suspension, a non-NSAID or non-corticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly protein-bound drugs with METACAM Oral Suspension has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of METACAM Oral Suspension has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.

Adverse Reactions: Field safety was evaluated in 306 dogs.¹ Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam.

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of frequency by body system:

Gastrointestinal: vomiting, anorexia, diarrhea, melena, gastrointestinal ulceration

Urinary: azotemia, elevated creatinine, renal failure

Neurological/Behavioral: lethargy, depression

Hepatic: elevated liver enzymes

Dermatologic: pruritus

Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with use of meloxicam in cats.

Information for Dog Owners: Meloxicam, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death (see Adverse Reactions). Owners should be advised to discontinue METACAM and contact their veterinarian immediately if signs of intolerance are observed.

The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.

Effectiveness: The effectiveness of meloxicam was demonstrated in two field studies involving a total of 277 dogs representing various breeds, between six months and sixteen years of age, all diagnosed with osteoarthritis. Both of the placebo-controlled, masked studies were conducted for 14 days. All dogs received 0.2 mg/kg meloxicam on day 1. All dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14 of both studies. Parameters evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Parameters assessed by owners included mobility, ability to rise, limping, and overall improvement.

In the first field study (n=109), dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all parameters. In the second field study (n=48), dogs receiving meloxicam showed a clinical improvement after 14 days of therapy for all parameters; however, statistical significance was demonstrated only for the overall investigator evaluation on day 7, and for the owner evaluation on day 14.¹

Reference: 1. FOI for NADA 141-213 METACAM (meloxicam oral suspension).

Approved by FDA under NADA # 141-213

Marketed by:

Boehringer Ingelheim Animal Health USA Inc.
Duluth, GA 30096

METACAM® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.
©2019 Boehringer Animal Health USA Inc. All rights reserved. US-PET-0402-2021

601413-05/601568-05
86998696/86998653
Revised 08/2019

Brief Summary

Metacam® (meloxicam)

5 mg/mL Solution for Injection
Non-steroidal anti-inflammatory drug for use in dogs and cats only

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Warning: Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information.

Description: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each mL of this sterile product for injection contains meloxicam 5.0 mg, alcohol 15%, glycofuro 10%, poloxamer 188 5%, sodium chloride 0.6%, glycine 0.5% and meglumine 0.3%, in water for injection, pH adjusted with sodium hydroxide and hydrochloric acid.

Indications: Dogs: METACAM Injection is indicated in dogs for the control of pain and inflammation associated with osteoarthritis.

Contraindications: Dogs with known hypersensitivity to meloxicam should not receive METACAM Injection.

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For IV or SQ injectable use in dogs. All dogs should undergo a thorough history and physical examination before administering any NSAID. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to, and periodically during use of any NSAID in dogs.

Owner should be advised to observe their dogs for signs of potential drug toxicity.

Precautions: The safe use of METACAM Injection in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating bitches has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. Safety has not been established for intramuscular (IM) administration in dogs. When administering METACAM Injection, use a syringe of appropriate size to ensure precise dosing. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after the administration of the total daily dose of METACAM Oral Suspension, a non-NSAID or noncorticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly protein-bound drugs with METACAM Injection has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of METACAM Injection has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. The effect of cyclo-oxygenase inhibition and the potential for thromboembolic occurrence or a hypercoagulable state has not been studied.

Adverse Reactions:

Dogs: A field study involving 224 dogs was conducted.¹ Based on the results of this study, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam.

The following adverse reactions are based on post-approval adverse drug event reporting. The categories are listed in decreasing order of frequency by body system:

Gastrointestinal: vomiting, diarrhea, melena, gastrointestinal ulceration

Urinary: azotemia, elevated creatinine, renal failure

Neurological/Behavioral: lethargy, depression

Hepatic: elevated liver enzymes

Dermatologic: pruritus

Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with the use of meloxicam in cats.

Information For Dog Owners: Meloxicam, like other NSAIDs, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with NSAID intolerance. Adverse reactions may include vomiting, diarrhea, lethargy, decreased appetite and behavioral changes. Dog owners should be advised when their pet has received a meloxicam injection. Dog owners should contact their veterinarian immediately if possible adverse reactions are observed, and dog owners should be advised to discontinue METACAM therapy.

Effectiveness: Dogs: The effectiveness of METACAM Injection was demonstrated in a field study involving a total of 224 dogs representing various breeds, all diagnosed with osteoarthritis.¹ This placebo-controlled, masked study was conducted for 14 days. Dogs received a subcutaneous injection of 0.2 mg/kg METACAM Injection on day 1. The dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14. Variables evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Variables assessed by owners included mobility, ability to rise, limping, and overall improvement. In this field study, dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all variables.

Reference: 1. FOI for NADA 141-219 METACAM (meloxicam) 5 mg/mL Solution for Injection.

Approved by FDA under NADA # 141-219

Marketed by:

Boehringer Ingelheim Animal Health USA Inc.
Duluth, GA 30096

METACAM is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.
US-PET-0402-2021

601307-09
Revised 09/2019
86560313